Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Description

The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure. This research may improve the way that radioembolization is performed, which could help people whose cancer has spread to the liver. The research may also provide information about how tumors respond to radioembolization.

Conditions

Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure. This research may improve the way that radioembolization is performed, which could help people whose cancer has spread to the liver. The research may also provide information about how tumors respond to radioembolization.

Correlation of Histopathological Findings With Radiation Exposure Levels After Y90 Transarterial Radioembolization (TARE) of Hepatic Metastases: A Feasibility Study

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Condition
Colon Cancer Liver Metastasis
Intervention / Treatment

-

Contacts and Locations

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * age ≥ 18 years
  • * Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • * histologically confirmed primary adenocarcinoma of the colon or rectum
  • * CLM considered unresectable or not amenable to percutaneous ablation
  • * existent tissue samples from a standard of care biopsy of the target tumor within 42 days prior to treatment OR clinical indication for biopsy at the time of the treatment under the institutional guidelines for progression of disease.
  • * adequate blood cell counts (WBC \> 1.5 x 109/L, platelet count \> 50 x 109/L)
  • * adequate renal function (creatinine \< 1.5 mg/dL)
  • * total bilirubin level ≤ 1.5 mg/dL
  • * prior hepatic radiotherapy (The lesion / lobe being treated cannot have had prior treatment with radiotherapy - untreated lesions / lobes in the liver may be evaluated under the protocol)
  • * severe cirrhosis
  • * severe portal hypertension
  • * uncorrectable flow to the gastrointestinal tract and/or \>30 Gy (or \>50 Gy in multiple sessions) radiation absorbed dose to the lungs

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Constantinos T Sofocleous, MD, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2024-12-07